Phase II study of sorafenib-regorafneib sequential therapy for the patients with advanced hepatocellular carcinoma previously treated with lenvatinib

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041190082

Enrollment

Registered

2019-11-21

Start date

2019-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma Hepatocellular carcinoma

Interventions

160 mg of oral regorafenib during weeks 1 to 3 of each 4 week cycle after 400 mg of sorafenib orally twice daily

Sorafenib, Regorafenib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; good liver functional reserve; 20 years old or older, ECOG Performance status <=2; preservation of major organ function; written informed consent

Exclusion criteria

Exclusion criteria: refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; unstable angina or myocardial infarction; severe complication; active infection; pregnant or lactating women and her partner, or women of childbearing potential; mental disorder; other factors unsuitable for participant

Design outcomes

Primary

Measure	Time frame
1-year survival rate	—

Secondary

Measure	Time frame
Progression-free survival, Overall survival, 6-months progression free-survival rate, Time to progression, Time to treatment failure, Overall response rate, Tumor control rate, Subsequent therapy, Adverse event	—

Contacts

Public ContactTakeshi Terashima

Kanazawa University Hospital

tera@m-kanazawa.jp+81-76-265-2235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026